In advanced NSCLC, Reck et al. [25] demonstrated that treatment with pembrolizumab was associated with significantly longer PFS, OS and fewer adverse events than platinum-based chemotherapy in patients with PD-L1 expression on at least 50% of tumor cells. This evidence concerns the gene CD274 and neoplasm.